Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem, Inc. (Nasdaq: VSTM) has announced the grant of stock options for 39,000 shares and restricted stock units (RSUs) for 22,500 shares to five new employees. This grant was made as an inducement for their employment and complies with Nasdaq Listing Rule 5635(c)(4). The options are priced at $1.26 per share, reflecting the closing price on October 1, 2020. Vesting of these awards will occur over four years, with 25% vesting after one year and the remainder vesting quarterly.
Verastem, Inc. (Nasdaq:VSTM) has sold its oral cancer drug COPIKTRA to Secura Bio for $70 million in cash, with potential additional earnings reaching $311 million based on regulatory and sales milestones. The company will also receive low double-digit royalties for U.S., European, and UK sales exceeding $100 million. This strategic move allows Verastem to focus on developing its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) programs targeting KRAS mutant solid tumors. The ongoing FRAME study shows promise, with registration-directed trials planned.